Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryFeb282022	Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress Enrollment Ongoing in Multi-dose, Multi-cycle Escalation Cohort of FT596+R at 900 Million Cells per Dose for R/R BCL; Interim Phase 1 Data of 16 Patients Showed 69% ORR and 56% CR in Single-dose Escalation Cohorts of FT596+R at ≥90 Million Cells Granted RMAT Designation for FT516 in R/R DLBCL; Read All »	View HTML
Toggle SummaryFeb282023	Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents, and Receivables Multi-dose Treatment Cohorts Initiated in FT576 Phase 1 Study for Multiple Myeloma; Interim Clinical Data from Single-dose Cohorts Showed Objective Responses and Selective Depletion of Activated Host Immune Cells Read All »	View HTML
Toggle SummaryFeb262024	Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus ; Study Start-up Ongoing at Multiple Clinical Sites First Patient Treated in Phase 1 Study of FT522 ADR-armed, CD19-targeted CAR NK Cell Program; Dose Escalation Read All »	View HTML
Toggle SummaryApr022024	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO , April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune Read All »	View HTML
Toggle SummaryMar052024	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO , March 05, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune Read All »	View HTML
Toggle SummaryFeb022024	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO , Feb. 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, Read All »	View HTML
Toggle SummaryDec132023	Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO , Dec. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, Read All »	View HTML
Toggle SummaryDec042020	Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma 3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response No Observed Events of Any Grade of Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome, or Graft-vs-Host Disease Six Doses of Read All »	View HTML
Toggle SummaryAug122014	Fate Therapeutics Reports Second Quarter 2014 Financial Results First Data Review in Phase 2 PUMA Study of PROHEMA Supports Continuation of Enrollment PROMPT and PROVIDE Studies of PROHEMA in Pediatric Patients to Initiate in 2H14 SAN DIEGO, Aug. 12, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the Read All »	View HTML Fate Therapeutics Reports Second Quarter 2014 Financial Results 29.6 KB
Toggle SummaryAug052015	Fate Therapeutics Reports Second Quarter 2015 Financial Results Interim Data From PROHEMA® PUMA Study Show Reduction in Severe Infections Across Multiple Pathogen Types First Pediatric Subject Treated in PROHEMA® PROVIDE Study of CNS Cellular Replacement Strategic Research Collaboration Formed With Juno Therapeutics to Identify Small Molecule Read All »	View HTML Fate Therapeutics Reports Second Quarter 2015 Financial Results 38.5 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.